Anatara Lifesciences

ANR.AX

Biotechnology · Healthcare

Exchange

Australian Securities Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Anatara Lifesciences is a small Australian biotechnology company focused on developing treatments for gut health problems. Its main work centers on gastrointestinal diseases, including a product called Detach aimed at reducing gut damage in cancer patients undergoing treatment. The company targets medical conditions where there are few good treatment options, working toward getting its drugs approved for use by patients and doctors.

Anatara makes no meaningful revenue yet and operates at a significant loss, which is typical for early-stage drug developers. It is based in Australia and is a very small company, with most of its funding coming from share issuances rather than product sales. The biggest risk the company faces is the uncertainty of clinical trials — if its drug candidates fail to prove safe and effective in testing, the company could run out of money before reaching the market.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+181.8% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+57.8% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

26.6%ownership

Insiders own a meaningful stake in the company

Cash Runway

~0 months

A$101,356 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Anatara Lifesciences grew revenue 182% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-96.1%

Weak — -96.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-10.9%

Shrinking sales (-10.9% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-181.2%

Burning cash (-181.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial